Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5653344 | 0.98 | SIGMAR1 (0.50) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL3681409 | 0.90 | SIGMAR1 (0.52) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL497585 | 0.78 | SIGMAR1 (0.46) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL20061130 | 0.74 | SIGMAR1 (0.56) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL20061148 | 0.74 | SIGMAR1 (0.56) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL13154126 | 0.73 | GAA (0.55) | SIGMAR1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL17479478 | 0.71 | SIGMAR1 (0.50) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL30624762 | 0.71 | SIGMAR1 (0.71) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL21243273 | 0.71 | SIGMAR1 (0.73) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL13537546 | 0.71 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC18A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1994 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122016983-A | Method for detecting multiple drugs in hair | 公安部鉴定中心 | 2026-05-12 | — | — | CN | claimed |
| CN-122028945-A | Apparatus, systems, and methods for aerosolized drug administration | GH研究爱尔兰有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260060949-A1 | METHOD FOR TREATING DAMAGE INDUCED BY SLEEP DEPRIVATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-03-05 | — | — | US | claimed |
| US-20250352538-A1 | PHARMACEUTICAL RESINATE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | RHODES PHARMACEUTICALS LP (US) | 2025-11-20 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| EP-4594294-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-08-06 | — | — | EP | claimed |
| US-12377065-B2 | Compositions for treatment of substance use disorder | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2025-08-05 | — | — | US | claimed |
| US-20250195537-A1 | PSYCHEDELIC DRUG TREATMENT OF NEUROPSYCHIATRIC DISORDERS AND CEREBRAL PALSY | FEIFEL DAVID (US) | 2025-06-19 | — | — | US | claimed |
| CN-117654455-B | Purifying and extracting composition, kit and method for determining drugs and fentanyl drugs in biological sample | 宁波市疾病预防控制中心(宁波市健康教育与促进中心) | 2025-06-10 | — | — | CN | claimed |
| EP-1242058-A1 | USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES | Pfizer Products Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020042446-A1 | Treatment of addiction and addiction-related behavior | BROOKHAVEN SCIENCE ASSOCIATES | 2002-04-11 | — | — | US | claimed |
| US-20020037925-A1 | Treatment of addiction and addiction-related behavior | BROOKHAVEN SCIENCE ASSOCIATES | 2002-03-28 | — | — | US | claimed |
| US-20020019421-A1 | Compositions and therapy for substance addiction | BIBERMAN RONI (IL) | 2002-02-14 | — | — | US | claimed |
| EP-1121591-A1 | IMMUNOASSAY THAT PROVIDES FOR BOTH COLLECTION OF SALIVA AND ASSAY OF SALIVA | Bogema, Stuart C. (US) | 2001-08-08 | — | — | EP | claimed |
| WO-2000015020-A9 | IMMUNOASSAY THAT PROVIDES FOR BOTH COLLECTION OF SALIVA AND ASSAY OF SALIVA | BOGEMA STUART C (US) | 2001-06-21 | — | — | WO | claimed |
| US-6248598-B1 | Immunoassay that provides for both collection of saliva and assay of saliva for one or more analytes with visual readout | BOGEMA STUART C (US) | 2001-06-19 | — | — | US | claimed |
| WO-2000059486-A2 | USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | claimed |
| WO-2000015020-A1 | IMMUNOASSAY THAT PROVIDES FOR BOTH COLLECTION OF SALIVA AND ASSAY OF SALIVA | BOGEMA STUART C (US) | 2000-03-23 | — | — | WO | claimed |
| WO-2000006139-A2 | USE OF MOCLOBEMIDE AND METABOLITES FOR TREATING AND PREVENTING SUBSTANCE ABUSE | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060949-A1 | METHOD FOR TREATING DAMAGE INDUCED BY SLEEP DEPRIVATION | ATP2A1, CHERP, ATP2A3 | SIGMAR1 927/4885TAAR1 4207/4885SLC18A2 794/4885 |
| US-12377065-B2 | Compositions for treatment of substance use disorder | PNMT, METTL3, BHMT2 | SIGMAR1 138/4885TAAR1 124/4885SLC18A2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.